Getting some media exposure - this from *. This is co-authored by MXC so, basically also advertising.
I noted that ArtemiC is a
"non-Canabis" natural product so MXC really has moved away from being a Cannabis company.
A huge leap for MGC Pharma as Covid-19 spray ArtemiC is included in the FDA’s National Drug Code Database - *Theinclusion of MGC Pharma’s ArtemiC into the FDA’s NDC database will fill animportant hole in the market between existing OTC products and expensive BigPharma drugs.
Europeanbased MGC Pharma (ASX:MXC) is set to expand its addressable market in the US after ArtemiC was listed as an over-the-counter (OTC) status on the FDA’s National Drug Code Database (NDC).
The OTC statusmeans that ArtemiC, MGC’s proprietary clinically tested COVID-19 treatment,could now be sold through the US Pharmacy Benefit Management (PBM) networksstarting in April.
The successful NDClisting was facilitated by MGC’s supply and distribution partner, AMC Pharma.
AMC is a SpecialPurpose Vehicle founded by experienced US healthcare professionals and formerfederal US government officials to promote the research and growth ofphyto-medicines in the US.
Now that the NDChas been listed, AMC is wasting no time negotiating shelf space for ArtemiCwith some of the largest US Pharmacy networks and independent pharmacies.
In addition, AMChas submitted a purchase order for US$2 million of ArtemiC with MGC forimmediate production and delivery in two installments over Q3 and Q4 of thisyear.
“The listing ofArtemiC as an OTC drug provides significant access to the largest healthcaremarket in the world, and stands as a major milestone MGC’s growth progression,”said MGC Pharma CEO, Roby Zomer.
“The receipt of anorder to the value of US$2m from our distribution partner, AMC, is a seriousendorsement for the product, which has a demonstrated capacity to relievesymptoms of COVID-19 and other inflammatory diseases.”
ArtemiC’s efficacy and safety
ArtemiC is anon-cannabis, all-natural medical spray developed by MGC Pharma – utilisingSwiss Pharmacan’s MyCell and GraftBio’s SNEDD technology that have been provento increase the bioavailability of the natural ingredients used in ArtemiC’sformulation.
The phyto-medicineformulation used in ArtemiC includes four naturally-based ingredientsconsisting of curcumin, boswellia serrata, artemisinin and Vitamin C.
In a Phase-2double-blind, placebo-controlled Clinical Trial on 50 patients with COVID-19,ArtemiC has demonstrated a full safety and efficacy profile with nodrug-adverse events.
The study concludedthat ArtemiC has the ability to prevent deterioration of COVID-19 patients andachieve faster clinical improvement, reducing pressure off the healthcaresystem.
Subsequent trialshave also proven ArtemiC to be an effective anti-inflammatory across a widerange of chronic diseases.
Filling a market gap
Today’s inclusionof ArtemiC into the FDA’s NDC database means that US patients are able to buy theproduct through the Pharmacy Benefit Management (PBM) network.
The PBM network hasmany benefits including cheaper costs, which help lower overall healthcarecosts for consumers and payers. The PBM also ensures that medications arechosen based on their safety, effectiveness, and value.
Meanwhile, the NDCdatabase provides a standardised format for drug information, which makes iteasier for healthcare providers to compare different drugs, and helps preventmedication errors.
Brent Yessin of AMCbelieves that securing NDC inclusion for ArtemiC will result in considerableimpact in the over-the-counter retail sector.
“Through ourpartnership with MGC, we are now able to offer the market a clinically proven,plant-based, and FDA authorised product that fills an important hole in themarket between existing OTC products and expensive prescription products fromBig Pharma,” Yessin said.
ArtemiC can befound on the FDA National Drug Code Directory under the code: 83278.
